Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers

Journal of Urology

Volumn 187, Issue 2, 2012, Pages 457-462

  Shariat, Shahrokh F ^a,b   Chromecki, Thomas F ^a,c   Cha, Eugene K ^a   Karakiewicz, Pierre I ^e   Sun, Maxine ^e   Fradet, Yves ^f   Isbarn, Hendrik ^g   Scherr, Douglas S ^a   Bastian, Patrick J ^h   Pummer, Karl ^c   Fajkovic, Harun ^a,d   Sagalowsky, Arthur I ^j   Ashfaq, Raheela ^j   Doblinger, Matthias ⁱ   Cote, Richard J ^k   Lotan, Yair ^j  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d University of Montreal ^*  (Austria)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

biological markers; cystectomy; recurrence; survival; urinary bladder neoplasms

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ACCURACY; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CARCINOMA IN SITU; CELL CYCLE; CONTROLLED STUDY; CYSTECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPHOVASCULAR INVASION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA;

EID: 84855612068     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.10.031     Document Type: Article

References (32)

1. S.F. Shariat, P.I. Karakiewicz, R. Ashfaq Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 112 2008 315
2. A.J. Levine, J. Momand, C.A. Finlay The p53 tumour suppressor gene Nature 351 1991 453
3. S.F. Shariat, Y. Lotan, P.I. Karakiewicz p53 predictive value for pT1-2 N0 disease at radical cystectomy J Urol 182 2009 907
4. S.P. Lerner, W. Stadler, S. Groshen Cell cycle regulatory protein alterations in a prospective study of patients with organ-confined bladder cancer following radical cystectomy J Urol 183 suppl. 2010 e662 abstract 1715
5. R.J. Cote, M.D. Dunn, S.J. Chatterjee Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53 Cancer Res 58 1998 1090
6. H.B. Grossman, M. Liebert, M. Antelo p53 and RB expression predict progression in T1 bladder cancer Clin Cancer Res 4 1998 829
7. C. Barbieri, Y. Lotan, R. Lee Tissue-based molecular markers for bladder cancer Minerva Urol Nefrol 62 2010 241
8. A.S. Sarkis, G. Dalbagni, C. Cordon-Cardo Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression J Natl Cancer Inst 85 1993 53
9. D. Esrig, D. Elmajian, S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259
10. J.P. Stein, D.A. Ginsberg, G.D. Grossfeld Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer J Natl Cancer Inst 90 1998 1072
11. H. Tokunaga, S.F. Shariat, A.E. Green Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens Int J Radiat Oncol Biol Phys 51 2001 16
12. W.F. Benedict, S.P. Lerner, J. Zhou Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer Oncogene 18 1999 1197
13. C. Cordon-Cardo, D. Wartinger, D. Petrylak Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer J Natl Cancer Inst 84 1992 1251
14. S.F. Shariat, H. Tokunaga, J. Zhou p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer J Clin Oncol 22 2004 1014
15. S.J. Chatterjee, R. Datar, D. Youssefzadeh Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma J Clin Oncol 22 2004 1007
16. C. Cordon-Cardo, Z.F. Zhang, G. Dalbagni Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors Cancer Res 57 1997 1217
17. S.F. Shariat, J. Kim, G. Raptidis Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder Urology 61 2003 1140
18. S.F. Shariat, V. Margulis, Y. Lotan Nomograms for bladder cancer Eur Urol 54 2008 41
19. S.F. Shariat, P.I. Karakiewicz, G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414
20. S.F. Shariat, G.S. Palapattu, P.I. Karakiewicz Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy Eur Urol 51 2007 137
21. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666
22. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis Hum Pathol 37 2006 1568
23. S.F. Shariat, A.R. Zlotta, R. Ashfaq Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness Mod Pathol 20 2007 445
24. R.J. Cote, D. Esrig, S. Groshen p53 and treatment of bladder cancer Nature 385 1997 123
25. N. Malats, A. Bustos, C.M. Nascimento P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 2005 678
26. P. Korkolopoulou, P. Christodoulou, A.E. Konstantinidou Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1 Hum Pathol 31 2000 751
27. P.M. Grambsch, T.M. Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 1994 515
28. F.E. Harrell Jr, R.M. Califf, D.B. Pryor Evaluating the yield of medical tests JAMA 247 1982 2543
29. F.E. Harrell Jr, K.L. Lee, D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361
30. S.C. Smith, A.S. Baras, J.K. Lee The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer Cancer Res 70 2010 1753
31. S. Madersbacher, W. Hochreiter, F. Burkhard Radical cystectomy for bladder cancer todaya homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690
32. R.E. Hautmann, J.E. Gschwend, R.C. de Petriconi Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era J Urol 176 2006 486